Oseltamivir for the Treatment of H1N1 Influenza During Pregnancy

被引：13

作者：

Beigi, R. H. ^{[1
,2
]}

Pillai, V. C. ^{[3
]}

Venkataramanan, R. ^{[2
,3
,4
]}

Caritis, S. N. ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA

[3] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Sch Med, Pittsburgh, PA 15261 USA

[4] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 98卷 / 04期

关键词：

PHARMACOKINETICS; SAFETY;

D O I：

10.1002/cpt.179

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any trimester of pregnancy and postpartum. Oseltamivir (Tamiflu) is currently the recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. Oseltamivir has been demonstrated to prevent disease after exposure, treat infected individuals, as well as lessen the likelihood of complications. The physiologic adaptations of pregnancy alter the pharmacokinetics of this important drug. Evidence of these alterations, knowledge gaps, and future investigative directions to fill these knowledge gaps are highlighted.

引用

页码：403 / 405

页数：3

共 17 条

[1] Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach [J].

Anderson, GD .

CLINICAL PHARMACOKINETICS, 2005, 44 (10) :989-1008

[2] Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies [J].

Andrew, M. A. ;

Easterling, T. R. ;

Carr, D. B. ;

Shen, D. ;

Buchanan, M. L. ;

Rutherford, T. ;

Bennett, R. ;

Vicini, P. ;

Hebert, M. F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :547-556

[3] Prevention and Management of Influenza in Pregnancy [J].

Beigi, Richard H. .

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2014, 41 (04) :535-+

[4] Pharmacokinetics of oseltamivir among pregnant and nonpregnant women [J].

Beigi, Richard H. ;

Han, Kelong ;

Venkataramanan, Raman ;

Hankins, Gary D. ;

Clark, Shannon ;

Hebert, Mary F. ;

Easterling, Thomas ;

Zajicek, Anne ;

Ren, Zhaoxia ;

Mattison, Donald R. ;

Caritis, Steve N. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 (06) :S84-S88

[5] Safety of Oseltamivir in Pregnancy A Review of Preclinical and Clinical Data [J].

Donner, Barbara ;

Niranjan, Viswanathan ;

Hoffmann, Gerhard .

DRUG SAFETY, 2010, 33 (08) :631-642

[6] Safety and pharmacology of oseltamivir in clinical use [J].

Dutkowski, R ;

Thakrar, B ;

Froehlich, E ;

Suter, P ;

Oo, C ;

Ward, P .

DRUG SAFETY, 2003, 26 (11) :787-801

[7] Pharmacokinetics of oseltamivir according to trimester of pregnancy [J].

Greer, Laura G. ;

Leff, Richard D. ;

Rogers, Vanessa Laibl ;

Roberts, Scott W. ;

McCracken, George H., Jr. ;

Wendel, George D., Jr. ;

Sheffield, Jeanne S. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 (06) :S89-S93

[8] Maternal and Neonatal Outcomes After Antepartum Treatment of Influenza With Antiviral Medications [J].

Greer, Laura G. ;

Sheffield, Jeanne S. ;

Rogers, Vanessa L. ;

Roberts, Scott W. ;

McIntire, Donald D. ;

Wendel, George D., Jr. .

OBSTETRICS AND GYNECOLOGY, 2010, 115 (04) :711-716

[9] Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 [J].

He, G ;

Massarella, J ;

Ward, P .

CLINICAL PHARMACOKINETICS, 1999, 37 (06) :471-484

[10] The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion - Correlation of in vivo and in vitro studies [J].

Hill, G ;

Cihlar, T ;

Oo, C ;

Ho, ES ;

Prior, K ;

Wiltshire, H ;

Barrett, J ;

Liu, BL ;

Ward, P .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (01) :13-19

← 1 2 →